N/A
Manufactured by Amneal Pharmaceuticals LLC
8,032 FDA adverse event reports analyzed
Last updated: 2026-04-15
GUANFACINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Amneal Pharmaceuticals LLC. The most commonly reported adverse reactions for GUANFACINE HYDROCHLORIDE include DRUG INEFFECTIVE, OFF LABEL USE, SOMNOLENCE, AGGRESSION, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GUANFACINE HYDROCHLORIDE.
Out of 4,100 classified reports for GUANFACINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 8,032 FDA FAERS reports that mention GUANFACINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, SOMNOLENCE, AGGRESSION, FATIGUE, TOXICITY TO VARIOUS AGENTS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Amneal Pharmaceuticals LLC in connection with GUANFACINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.